FDA Approves Aducanumab — A Controversial Drug For Alzheimer's

FDA Approves Aducanumab — A Controversial Dru...

Up next

Vaccinated or not, we’re on the brink of a measles epidemic

Measles is making a comeback. Ongoing outbreaks in Pennsylvania, South Carolina, Texas, and Utah have documented hundreds of cases, mostly among unvaccinated people. And while local and federal politicians debate the definitions and impact of those measles-associated deaths, heal ...  Show more

The science of self-worth (and how to boost yours)

Your self-worth today can be affected by your memories. But you have power over those memories – when you re-experience them. By doing that, you can reshape your self-esteem for the better and change your perspective. That idea and the broader science of self-worth are at the hea ...  Show more

Recommended Episodes

'Some Hope Is Better Than Having No Hope'
The Daily

When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.

But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cogni ...

  Show more

Controversial new Alzheimer's drug in the spotlight
Business Daily

After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ...  Show more

Alzheimer’s drug has experts divided; rising ICE use in Australia; the disappointing results of a study aimed at improving ovarian cancer survival rates
Health Report - Full program podcast

This week, the first of a new series on substance use and what you need to know about ICE - crystal meth. Does early diagnosis of ovarian cancer through screening make a difference to survival rates? And the search for an Alzheimer's disease treatment is as controversial as ever. ...  Show more

Audio long read: Conquering Alzheimer’s — a look at the therapies of the future
Nature Podcast

Last year, researchers announced that the Alzheimer’s drug lecanemab lowered the amount of amyloid protein plaques associated with the disease in the brains of participants in a clinical trial, and slowed their cognitive decline.Now, researchers are looking to drug combinations, ...  Show more